MAO-B-IN-48 

MAO-B-IN-48 is a selective MAO-B inhibitor (IC₅₀ = 0.09 μM, K_i = 0.02 μM). MAO-B-IN-48 exhibits inhibitory activity against hBChE (IC₅₀ = 1.10 μM, K_i = 0.43 μM) and AChE (IC₅₀ = 0.56 μM, K_i = 0.14 μM). MAO-B-IN-48 suppresses self-induced aggregation of toxic β-amyloid peptides and exerts antioxidant activity, including DPPH radical scavenging, CUPRAC copper ion reduction, and superoxide anion scavenging. MAO-B-IN-48 can be used for the study of Alzheimer's disease (AD)^[1].

MAO-B-IN-48 (Compound 1d-R) inhibits self-induced aggregation of Aβ_1-40 (IC₅₀ = 31.42 μM) and Aβ_1-42 (IC₅₀ = 21.32 μM) in vitro^[1].
MAO-B-IN-48 shows DPPH radical scavenging activity (IC₅₀ = 3.40 mM), antioxidant activity in the CUPRAC assay (IC₅₀ = 33.40 μM) and superoxide anion scavenging capacity (IC₅₀ = 28.21 μM)^[1].
MAO-B-IN-48 (1-25 μM) does not exhibit cytotoxic effects on HepG2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MAO-B-IN-48 (20 mg/kg, i.g., 1 week) ameliorates the cognitive impairment induced by AlCl3 in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

350.48

C₂₁H₂₂N₂OS

C[C@H](C1=CC=CC2=C1C=CC=C2)NC(OC3=CC(N(C)C)=CC=C3)=S

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Teke Tuncel S, et al. Multitarget-directed carbamate and carbamothioate derivatives: Cholinesterase and monoamine oxidase inhibition, anti-β-amyloid (Aβ) aggregation, antioxidant and blood-brain barrier permeation properties against Alzheimer's disease. Eur J Med Chem. 2025 Nov 15;298:117986.